Phathom Pharmaceuticals, Inc. (PHAT) Tops Q4 EPS by 27c

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q4 EPS of ($0.80), $0.27 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $680 thousand versus the consensus estimate of $708.61 thousand.

For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c